New methods to produce human monoclonal antibodies
type: Dataset
description: The number of monoclonal antibodies used as drug or under clinical investigation increases rapidly. The first murine monoclonal antibodies (mAbs) used in therapy induces human anti-mouse antibodies (HAMAs) when administered to patients. Such HAMAs hamper the therapeutic efficacy of mAbs and induce side effects. To limit these effects, new antibodies were developed during the, last 30 years. Chimeric, humanized and fully human antibodies were engineered. The use of human monoclonal antibodies (hAbs) appears ideal to solve the problem of HAMAs. Nowadays 9 fully human antibodies are available and others are evaluated in clinical trials or currently investigated in research labs. Three methods exist to produce fully human antibodies: the phage display, the transgenic mice and the use of human B lymphocytes. The majority of fully human antibodies resulted from the phage display and the transgenic mice methods. The use of human B lymphocytes is less investigated due to a poor yield and stability problems. These last years, the immortalization process, thanks to the involvement of the Epstein-Barr virus and human myeloma, induced a rise of interest for human B lymphocytes. In this context we decided to develop fully human monoclonal antibodies using human B lymphocytes through immortalization using the Epstein-Barr virus followed or not by an immortalization with a human/mouse heteromyeloma HM. The first approach is based on hAbs production from peripheral blood memory B lymphocytes isolated from infected or vaccinated donors. The Staphylococcus aureus enterotoxine B (SEB) was used as a model. Memory B lymphocytes were purified and cultured in the presence of Epstein-Barr virus (EBV). The transformation of memory B lymphocytes by EBV allowed the generation of immortalized B lymphocytes lines producing IgGs antibodies directed against SEB. We succeeded in isolating 6 EBV-immortalized memory B lymphocytes lines secreting anti-SEB IgGs antibodies. After many attempts to immor…
identifier: NNT: 2012PA114857
issued: 2026-05-10T22:01:07.975324
language: fr
modified: 2026-05-10T22:01:07.975329
contact point: Organization
  fn: CCSD
keyword: anticorps-humains
keyword: anticorps-therapeutiques
keyword: b-lymphocyte
keyword: fusion
keyword: human-antibodies
keyword: immortalisation
keyword: immunisation-in-vitro
keyword: immunization
keyword: infoeu-reposemanticsdoctoralthesis
keyword: lymphocytes-b
keyword: sdvmheplife-sciences-q-biohuman-health-and-pathology
keyword: theses
landing page: https://theses.hal.science/tel-00829106

New methods to produce human monoclonal antibodies
type: Distribution
format: HTML
issued: 2026-05-10T22:01:07.989936
modified: 2026-05-10T22:01:07.897762
access URL: https://theses.hal.science/tel-00829106

test_moissonnage_selune
type: Agent